InterCure (INCR.TA) Stock Price
InterCure Price
Over the last 19 years InterCure grew revenue by 14.3% annually, reaching 238.85 M ILS. Earnings per share have declined at 24.6% per year over the last 10 years. For InterCure, the net margin of -28.4% is up versus -57.2% a few years ago. The consensus 12-month price target for InterCure is 7.14 ILS, about 50.5% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
InterCure stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
InterCure business model & stock analysis
Frequently asked questions about InterCure
InterCure Ltd is a leading company in the healthcare sector. The business model of InterCure revolves around the development and commercialization of innovative medical solutions to improve patient outcomes. With a strong focus on research and development, InterCure aims to provide advanced therapeutic solutions in areas such as respiratory, cardiovascular, and sleep disorders. The company's commitment to excellence and cutting-edge technology enables it to meet the evolving healthcare needs of individuals worldwide. With a customer-centric approach and a dedication to improving quality of life, InterCure Ltd stands out as a prominent player in the healthcare industry.
InterCure Ltd is primarily active in the medical cannabis industry.
The main competitors of InterCure Ltd in the market include established companies such as GW Pharmaceuticals, Tilray Inc., and Canopy Growth Corporation. These companies also operate within the medical cannabis industry and compete with InterCure in terms of product development, market share, and innovation. InterCure aims to differentiate itself by offering unique medical cannabis products and focusing on research and development to provide enhanced solutions for patients. Despite facing competition from various industry players, InterCure Ltd continues to strive for growth and maintain its market position through strategic partnerships and constant advancements in the field.
InterCure Ltd, a leading Israeli medical cannabis company, was founded in 2011. With a focus on improving patients' quality of life, InterCure is dedicated to research, development, production, and distribution of medical cannabis products. The company operates under the brand name "Canndoc" and holds a distinctive presence in both domestic and international markets. With a commitment to excellence, InterCure continuously strives to enhance patient care through its state-of-the-art cultivation facilities, advanced research initiatives, and partnerships with renowned international experts. With a rich history of innovation and a commitment to improving global healthcare, InterCure Ltd has established itself as a prominent player in the medical cannabis industry.
InterCure Ltd has achieved several significant milestones since its establishment. The company successfully developed and launched the innovative RESPeRATE device, a non-drug, FDA-cleared solution for hypertension. Additionally, InterCure Ltd has expanded its global presence, establishing partnerships and distribution channels in various markets. The company continues to enhance its product portfolio, offering advanced technologies and solutions to address various medical conditions. InterCure Ltd has also experienced notable financial growth and recognition, attracting investments and receiving prestigious awards for its advancements in healthcare. Overall, the company's milestones highlight its commitment to revolutionizing medical treatments and improving patients' well-being.
InterCure Ltd is primarily present in Israel, the United States, Canada, and Germany.
InterCure Ltd represents a strong commitment to promoting wellness and improving quality of life. The company values include innovation, integrity, and excellence. InterCure focuses on developing and commercializing therapeutic solutions that address unmet medical needs, particularly in the fields of respiratory disease and wellness. The corporate philosophy of InterCure revolves around advancing healthcare through cutting-edge technologies and research. With a dedicated team, InterCure aims to revolutionize the way illnesses are managed and to provide accessible treatments for better health outcomes. interCure Ltd is driven by its mission to enhance well-being and empower individuals to live healthier, more fulfilling lives.
Analysts currently set an average price target of 7.14 ILS for the InterCure stock (median: 7.14 ILS), implying -50.5 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the InterCure stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect InterCure to generate revenue of 574.00 M ILS and earnings per share of 1.70 ILS.
Converted at the current exchange rate, the InterCure share trades at 4.15 EUR (14.41 ILS).
The InterCure share (INCR.TA) is listed on 2 stock exchanges, including: NASDAQ (INCR).
InterCure Ltd was founded in 2000 to offer innovative digital health solutions. The company is based in Israel and provides various products and services targeting telemedicine, chronic diseases, and lifestyle management. Telemedicine InterCure offers an award-winning telemedicine platform called "CardioCare". This platform allows doctors to diagnose, treat, and monitor patients with high blood pressure without them having to come to a clinic. The platform includes a wireless blood pressure monitor connected to the patient's "CardioCare" app. By using this technology, the doctor can monitor the patient's blood pressure in real time and adjust the medication accordingly. Chronic diseases InterCure also offers products for managing chronic diseases such as asthma, diabetes, and COPD. The "RespeRate" is a breathing training device designed for patients with respiratory diseases. The device helps regulate breathing rhythm and patterns to improve the quality of breath and reduce symptoms. Lifestyle management Another product offered by InterCure is "Relaxing Moments". This app includes audio and video content for stress management and relaxation. The app was developed in collaboration with leading relaxation and stress reduction experts and includes exercises for breathing, meditation, and mindfulness. InterCure has also partnered with the company "Glucovation" to develop a "Smart Patch" for diabetics. This patch continuously measures blood glucose levels and sends this data to an app on the patient's smartphone. Through these continuous measurements, the patient can adjust medication in real time. Overall, InterCure offers a wide range of products and services aimed at improving patients' health and well-being. By utilizing digital technology, telemedicine, and collaborating with experts in various fields, InterCure supports patients in managing chronic diseases, relaxation, and disease prevention.
The expected revenue of InterCure is 574.00 M ILS. This figure is based on current financial data and reflects the company's business performance.
The expected profit of InterCure is 78.13 M ILS. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of InterCure is currently 8.46. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the InterCure stock.
The price-to-sales ratio (P/S) of InterCure is currently 1.15. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the InterCure stock.
The Eulerpool Quality Score for InterCure is 1/10.
The ISIN of InterCure is IL0011063760. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of InterCure is A1CZA8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of InterCure is INCR.TA. The ticker symbol is used to trade InterCure shares on the stock exchange.
InterCure stock
InterCure Peer Group
InterCure Ticker
InterCure FIGI
All fundamentals and in-depth analysis of InterCure
Our stock analysis for InterCure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InterCure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.